LEO Pharma A/S and NeoPharm Co. Ltd. announced that the companies have entered into a 10 year's agreement of supply and distribution of a selection of skin care products within NeoPharm's range of products. Under the terms of the agreement, products will be manufactured and supplied by NeoPharm and marketed and distributed by LEO Pharma as non-prescription skin care under a LEO Pharma trademark.

NeoPharm has developed the products using their proprietary technology MLE (Multi-Lamellar Emulsion), Defensamide and ADfence-P. LEO Pharma will have the rights to market the products globally - except for Korea, Thailand, Indonesia, Pakistan, Singapore, Malaysia, UAE and the Philippines. LEO Pharma is increasing its focus on meeting the unmet needs of people living with skin diseases. By entering partnerships with innovative companies, like NeoPharm, LEO Pharma wants to bring new dermatology solutions to patients - faster.

Spain will be the first of several markets to gain access to the new LEO Pharma emollients portfolio. This is expected to happen during 2015.